PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer

Published:2016-05 Issue:2 Volume:141 Page:293-302
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Webb John R.,Milne Katy,Kroeger David R.,Nelson Brad H.

Funder

Canadian Institutes of Health Research

U.S. Department of Defense

Canadian Cancer Society Research Institute

BC Cancer Foundation

BC Cancer Agency Tumour Tissue Repository

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference40 articles.

1. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application;Okazaki;Nat. Immunol.,2013

2. PD-1 signaling in primary T cells;Riley;Immunol. Rev.,2009

3. PD-1/PD-L1 inhibitors;Sunshine;Curr. Opin. Pharmacol.,2015

4. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer;Hamanishi;J. Clin. Oncol.,2015

5. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012

Cited by 270 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

2. Single‑cell and bulk RNA sequencing identifes T cell marker genes to predict the prognosis of ovrian caner;2024-08-11

3. Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial;Nature Communications;2024-07-16

4. Adoptive T cell therapy for ovarian cancer;Gynecologic Oncology;2024-07

5. The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study;Gynecologic Oncology;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3